BPC-157 Peptide

Overview

Gastric-derived pentadecapeptide with preclinical signal on tendon, ligament, and gut repair. Run as a supervised, time-limited cycle, not a lifelong protocol.

Key benefits

• 01
  Compelling preclinical data on tendon and ligament repair
• 02
  Short, cycled protocols - no open-ended dosing
• 03
  Eligibility paired with imaging or clinical rehab plan where relevant
• 04
  Labs bracket every cycle, same as NAD+

Clinical rationale

BPC-157 is a synthetic peptide derived from a gastric protein with documented preclinical activity on angiogenesis, NO-pathway signaling, and growth-factor expression in tendon and mucosal tissue. Human clinical evidence is limited to small series. ALUKARD offers it as a supervised 4-6 week cycle for specific recovery indications, not as a standing order.

Fit check

Using it well

Safety notes

• Prescription products require clinical eligibility and provider approval.
• Medication availability varies by state and clinical criteria.
• Research peptide - human efficacy data is limited.

Questions

• Is this FDA-approved?+

  No. BPC-157 is a research peptide with strong preclinical data and limited human trials. We offer it as a supervised, time-limited option with clear eligibility and labs - not as a consumer supplement.
• How long is a cycle?+

  Typically 4-6 weeks. Longer windows rarely improve outcomes and start to outrun the available safety data. A second cycle is possible after a wash-out if indicated.
• BPC-157 vs TB-500?+

  Different mechanisms, different evidence base. BPC-157 has more published tendon and GI signal; TB-500 sits earlier on the evidence curve. We choose based on the specific case, not a generic stack.
• Who gets declined?+

  Active oncology cases, pregnancy, members expecting lifelong dosing, or anyone without a concrete indication beyond general biohacking curiosity.